Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light
Authors:
- Maureen G. ConlanMCMaureen G. Conlan
- the SPRINT Study GroupTGthe SPRINT Study Group
- 22 December 2005
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 46 (1) , 24-33
Abstract
The SPRINT trial examined efficacy and safety of photochemically treated (PCT) platelets (PLTs). PCT PLTs were equivalent to untreated (control) PLTs for prevention of bleeding. Transfused PLT dose and corrected count increments (CIs), however, were lower and transfusion intervals were shorter for PCT PLTs, resulting in more PCT than control transfusions. PLT dose was analyzed to determine the impact of the number of PLTs transfused on transfusion requirements. Transfusion response was compared for patients with all doses of >or=3.0 x 10(11) and the complementary subset of patients with any dose of fewer than 3.0 x 10(11). Analyses included comparison of bleeding, number of PLT and red blood cell (RBC) transfusions, transfusion intervals, and CIs between PCT and control groups within each PLT dose subset. Mean PLT dose per transfusion in the PCT group was lower than in the control group (3.7 x 10(11) vs. 4.0 x 10(11); p<0.001). More PCT patients received PLT doses of fewer than 3.0 x 10(11) (n=190) than control patients (n=118; p<0.01). Comparisons of patients receiving comparable PLT doses showed no significant differences between PCT and control groups for bleeding or number of PLT or RBC transfusions; however, transfusion intervals and CIs were significantly better for the control group. When patients were supported with comparable doses of PCT or conventional PLTs, the mean number of PLT transfusions was similar. Lower CIs and shorter transfusion intervals for PCT PLTs suggest that some PLT injury may occur during PCT. This injury does not result in a detectable increase in bleeding, however.Keywords
This publication has 20 references indexed in Scilit:
- Recovery and life span of 111indium‐radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S‐59) and ultraviolet A lightTransfusion, 2004
- Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT TrialBlood, 2004
- Improving the bacteriological safety of platelet transfusionsTransfusion Medicine Reviews, 2004
- Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trialBlood, 2002
- Prevention of transfusion-associated graft-versus-host disease by inactivation of T cells in platelet componentsSeminars in Hematology, 2001
- Fundamentals of the psoralen-based Helinx™ technology for inactivation of infectious pathogens and leukocytes in platelets and plasmaSeminars in Hematology, 2001
- Oversight and Monitoring of Blood Safety in the United StatesVox Sanguinis, 1999
- Photochemical Treatment of Platelet Concentrates with a Novel Psoralen and UVA to Enhance the Safety of Platelet TransfusionsaTransfusion Medicine and Hemotherapy, 1998
- The Problem of Thrombocytopenia after Hematopoietic Stem Cell TransplantationStem Cells, 1996
- Blood Product-Associated Bacterial SepsisTransfusion Medicine Reviews, 1991